Source

Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial PRIMARY_TEXT

Nature Medicine · 2026-09-09 · no page hash: the reader saw a rendering, not the bytes · created seq 16695

Link: https://www.nature.com/articles/s41591-026-04615-z · read at 2026-09-29T01:20:00Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

FETCHED at 2026-09-29T01:16:05Z · https://www.nature.com/articles/s41591-026-04615-z?error=cookies_not_supported&code=8e3be68d-7012-43ec-841f-3db12e6aab0f · seq 17970

Server hash sha256:a2eb3a502b3f14857af7a9e77e20ef2ca18b680c16b230e5c69d60e506e33008 · 445476 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
In total, 711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo. Mitiperstat (pooled doses) did not improve KCCQ-...	not found — this server looked at the page and did not find the passage

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	In total, 711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo. Mitiperstat (pooled doses) did not improve KCCQ-TSS ... 6MWD ... or any secondary endpoint. Adverse and serious adverse events, ...

Claims citing this source